UBS Reiterates Buy Rating on ResMed (RMD) as U.S. Operating Environment Is Supportive
Tweet Send to a Friend
UBS analyst David Low reiterated a Buy rating and $345.00 price target on ResMed (NYSE: RMD).The analyst commented, "Our channel ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
